Immunoglobulin prophylaxis in pediatric hematopoietic stem cell transplant

Foster, Jennifer; Cheng, Wen-Sheng; Nguyen, Ngoc-Yen; Krance, Robert A.; Martinez, Caridad

doi:10.1002/pbc.27348

Cited by 15 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CMV was managed using preemptive approach by doing weekly PCR tests with threshold of detecting 20 iu/mL, patients were treated if CMV PCR > 250 iu/mL in high risk patients or 500 iu/mL in low risk patients. Ursodiol (10 mg/kg/dose PO BID) was started few weeks prior to transplant and continued till day +90 10–13 …”

Section: Methodsmentioning

confidence: 99%

Comparing between HLA‐matched sibling donor allogenic HSCT and non‐sibling matched related donor allogenic HSCT outcome in pediatric patients; single center retrospective study

Essa,

Alghazwani,

Abujoub

et al. 2024

Pediatric Transplantation

View full text Add to dashboard Cite

BackgroundExtended family donor search other than siblings may yield an HLA matched donor in communities with high rate of consanguinity. The outcome of patients who are transplanted from non‐sibling matched related donors (NS‐MRD) including engraftment and graft versus host disease (GVHD) are scarce in comparison with matched sibling donor (MSD).MethodsWe retrospectively reviewed the outcome of all our pediatric hematopoietic stem cell transplantation (HSCT) patients who had non‐sibling matched related donor and controlled them with matched sibling donor HSCT (based on age, indication of HSCT, conditioning regimen, GVHD prophylaxis, serotherapy, stem cell source and cytomegalovirus status).ResultsA total of 76 patients were reviewed during study period. Thirty patients (39.5%) in NS‐MRD arm and 46 patients in MSD (60.5%) were identified after matching in age, disease, and conditioning regimens. All patients had similar approach including stem cell source and GVHD prophylaxis (CNI + 2nd agent). Out of the NS‐MRD group, 18 patients (59%) had one of their parents as a donor and the rest as second degree relatives. Both groups were equally distributed and were homogeneous. Both groups had no statistically significant difference in outcome including engraftment, GVHD and Chimerism tests results. GVHD was seen in (13%) NS‐MRD patients compared to (11%) in MSD patients. All patients remain alive with median follow up of 1249 days (431–3525).ConclusionsThis study showed no significant difference in allogenic HSCT outcomes between matched sibling donors and non‐sibling matched related donors and support using the same management approach in terms of conditioning therapy, GVHD prophylaxis, and serotherapy only if indicated.

show abstract

Section: Methodsmentioning

confidence: 99%

Comparing between HLA‐matched sibling donor allogenic HSCT and non‐sibling matched related donor allogenic HSCT outcome in pediatric patients; single center retrospective study

Essa,

Alghazwani,

Abujoub

et al. 2024

Pediatric Transplantation

View full text Add to dashboard Cite

show abstract

“…However, recent research has failed to clearly support the role of IVIG these patients ( 75 – 77 ). Current pediatric HSCT guidelines recommend IVIG therapy only in cases of hypogammaglobulinemia ( 78 , 79 ).…”

Section: General Management Strategiesmentioning

confidence: 99%

Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review

et al. 2022

View full text Add to dashboard Cite

Cytomegalovirus (CMV), like other herpesviruses, has the unique ability to establish latent infection with subsequent reactivation during periods of stress and immunosuppression. Herpesviruses cause potentially devastating disease, particularly in hematopoietic stem cell transplant (HSCT) recipients. CMV is especially of concern in HSCT recipients given the high community seroprevalence, high risk of reactivation and high risk of transmission from HSCT donors to recipients causing primary infection after transplantation. The risk of CMV infection and severity of CMV disease varies depending on the underlying disease of the HSCT recipient, donor and recipient CMV status prior to HSCT, type of conditioning therapy in preparation for HSCT, allogeneic versus autologous HSCT, donor graft source, timing of infection in relation to HSCT, and other patient comorbidities. Different strategies exist for prevention (e.g., preemptive therapy vs. universal prophylaxis) as well as management of CMV disease (e.g., antiviral therapy, augmenting immune reconstitution, cytotoxic T-cell therapy). The purpose of this narrative review is to discuss diagnosis, prevention, and management of CMV infection and disease at different stages of HSCT, including key points illustrated through presentations of complex cases and difficult clinical scenarios. Traditional and novel strategies for CMV management will be discussed in the context of these unique clinical cases.

show abstract

“…Subsequently, passive antibody administration has been used to treat those infected with various microorganisms including bacteria, fungi, and viruses. Modern formulations of intravenous immunoglobulin (IVIG), pooled from thousands of healthy donors, is still used to prevent viral infections in certain patient populations [9,10]. As such, it is logical to consider the use of passive antibody transfer to treat patients in the current pandemic.…”

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic

Sullivan

Roback

2020

Transfusion Medicine Reviews

View full text Add to dashboard Cite

Immunoglobulin prophylaxis in pediatric hematopoietic stem cell transplant

Abstract: Dosing IVIG to maintain an IgG level > 400 mg/dl is a cost-effective and safe way to prevent viral infections in pediatric patients undergoing HSCT.

Cited by 15 publications

References 9 publications

Comparing between HLA‐matched sibling donor allogenic HSCT and non‐sibling matched related donor allogenic HSCT outcome in pediatric patients; single center retrospective study

Comparing between HLA‐matched sibling donor allogenic HSCT and non‐sibling matched related donor allogenic HSCT outcome in pediatric patients; single center retrospective study

Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review

Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic

Contact Info

Product

Resources

About